1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
2 Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321(7260): 531-535, 2000. PMID: 10968812. DOI: 10.1136/bmj.321.7260.531
3 Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y and Sugihara K: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus s-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): An open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14(13): 1278-1286, 2013. PMID: 24225157. DOI: 10.1016/s1470-2045(13)70490-x
4 Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L and Falcone A: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17): 1609-1618, 2014. PMID: 25337750. DOI: 10.1056/NEJMoa1403108
5 Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N and Hyodo I: Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27(8): 1539-1546, 2016. PMID: 27177863. DOI: 10.1093/annonc/mdw206
6 Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G and Li S: Urocortin’s inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26(4): 359-368, 2008. PMID: 18443956. DOI: 10.1080/07357900701788106
7 Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, Jeschke U, Paraskevaidis EA, Fountzilas G, Chrousos GP, Pavlidis N and Makrigiannakis A: Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FASL regulation. Br J Cancer 97(5): 637-645, 2007. PMID: 17667919. DOI: 10.1038/sj.bjc.6603918
8 Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G and Navarra P: Crh inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143(3): 807- 813, 2002. PMID: 11861501. DOI: 10.1210/endo.143.3.8694
9 Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA and Merseburger AS: The involvement of altered corticotropin- releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 69(4): 443-448, 2009. DOI: 10.1002/pros.20892
10 Tezval H, Jurk S, Atschekzei F, Becker JU, Jahn O, Serth J and Kuczyk MA: Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: Disruption of an endogenous inhibitor of angiogenesis and proliferation. World J Urol 27(6): 825-830, 2009. PMID: 19058138. DOI: 10.1007/s00345-009-0417-x
11 Akiyoshi K, Kamada M, Fujioka K, Ikeda K, Tojo K and Manome Y: Expression of mrnas of urocortin in the STKM-1 gastric cancer cell line. Anticancer Res 33(12): 5289-5294, 2013. PMID: 24324061.
12 Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G and Navarra P: Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 264(1-2): 44- 49, 2007. PMID: 17097220. DOI: 10.1016/j.mce.2006.10.006
13 Jin L, Chen C, Guo R, Wan R and Li S: Role of corticotropin- releasing hormone family peptides in androgen receptor and vitamin D receptor expression and translocation in human breast cancer MCF-7 cells. Eur J Pharmacol 684(1-3): 27-35, 2012. PMID: 22494987. DOI: 10.1016/j.ejphar.2012.03.034
14 Kamada M, Ikeda K, Fujioka K, Akiyama N, Akiyoshi K, Inoue Y, Hanada S, Yamamoto K, Tojo K and Manome Y: Expression of mRNAs of urocortin and corticotropin-releasing factor receptors in malignant glioma cell lines. Anticancer Res 32(12): 5299-5307, 2012. PMID: 23225430.
15 Miceli F, Ranelletti FO, Martinelli E, Petrillo M, Scambia G, Navarra P and Ferrandina G: Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Mol Cell Endocrinol 305(1-2): 6-11, 2009. PMID: 19433256. DOI: 10.1016/j.mce.2009.02.013
16 Reubi JC, Waser B, Vale W and Rivier J: Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88(7): 3312-3320, 2003. PMID: 12843181. DOI: 10.1210/jc.2002-021853
17 Ikeda K, Fujioka K, Tachibana T, Kim SU, Tojo K and Manome Y: Secretion of urocortin I by human glioblastoma cell lines, possibly via the constitutive pathway. Peptides 63: 63-70, 2015. PMID: 25239507. DOI: 10.1016/j.peptides.2014.09.007
18 Rodriguez JA, Huerta-Yepez S, Law IK, Baay-Guzman GJ, Tirado-Rodriguez B, Hoffman JM, Iliopoulos D, Hommes DW, Verspaget HW, Chang L, Pothoulakis C and Baritaki S: Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/STAT3 signaling. Cell Mol Gastroenterol Hepatol 1(6): 610-630, 2015. PMID: 26495412. DOI: 10.1016/j.jcmgh.2015.08.001
19 Ducarouge B, Pelissier-Rota M, Laine M, Cristina N, Vachez Y, Scoazec JY, Bonaz B and Jacquier-Sarlin M: CRF2 signaling is a novel regulator of cellular adhesion and migration in colorectal cancer cells. PLoS One 8(11): e79335, 2013. PMID: 24260200. DOI: 10.1371/journal.pone.0079335
20 Pelissier-Rota M, Chartier NT, Bonaz B and Jacquier-Sarlin MR: A crosstalk between muscarinic and CRF2 receptors regulates cellular adhesion properties of human colon cancer cells. Biochim Biophys Acta 1864(7): 1246-1259, 2017. PMID: 28432022. DOI: 10.1016/j.bbamcr.2017.04.008
21 Liu Y, Fang X, Yuan J, Sun Z, Li C, Li R, Li L, Zhu C, Wan R, Guo R, Jin L and Li S: The role of corticotropin-releasing hormone receptor 1 in the development of colitis-associated cancer in mouse model. Endocr Relat Cancer 21(4): 639-651, 2014. PMID: 25015995 . DOI: 10.1530/erc-14-0239
22 Deussing JM and Chen A: The corticotropin-releasing factor family: Physiology of the stress response. Physiol Rev 98(4): 2225- 2286, 2018. PMID: 30109816. DOI: 10.1152/physrev.00042.2017
23 Bale TL and Vale WW: CRF and CRF receptors: Role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557, 2004. PMID: 14744257. DOI: 10.1146/annurev. pharmtox.44.101802.121410
24 Chatzaki E, Lambropoulou M, Constantinidis TC, Papadopoulos N, Tache Y, Minopoulos G and Grigoriadis DE: Corticotropin- releasing factor (CRF) receptor type 2 in the human stomach: Protective biological role by inhibition of apoptosis. J Cell Physiol 209(3): 905-911, 2006. PMID: 16972272. DOI: 10.1002/jcp.20792
25 Dedic N, Chen A and Deussing JM: The CRF family of neuropeptides and their receptors - mediators of the central stress response. Curr Mol Pharmacol 11(1): 4-31, 2018. PMID: 28260504. DOI: 10.2174/1874467210666170302104053
26 Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, Scheimann J and Myers B: Regulation of the hypothalamic- pituitary-adrenocortical stress response. Compr Physiol 6(2): 603- 621, 2016. PMID: 27065163. DOI: 10.1002/cphy.c150015
27 Davidson SM, Rybka AE and Townsend PA: The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family. Biochem Pharmacol 77(2): 141-150, 2009. PMID: 18817752. DOI: 10.1016/j.bcp.2008.08.033
28 Taché Y and Perdue MH: Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 16 Suppl 1: 137-142, 2004. PMID: 15066020. DOI: 10.1111/j.1743-3150.2004.00490.x
29 Martinez V and Taché Y: CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 12(31): 4071-4088, 2006. PMID: 17100612. DOI: 10.2174/138161206778743637
30 Gourcerol G, Wu SV, Yuan PQ, Pham H, Miampamba M, Larauche M, Sanders P, Amano T, Mulak A, Im E, Pothoulakis C, Rivier J, Taché Y and Million M: Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents. Gastroenterology 140(5): 1586-1596.e1586, 2011. PMID: 21277852. DOI: 10.1053/j.gastro.2011.01.039
31 Baigent SM: Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides 22(5): 809-820, 2001. PMID: 11337095. DOI: 10.1016/s0196-9781(01)00395-3
32 Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC and Townsend PA: Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. Cancer Med 6(2): 408-415, 2017. PMID: 28109061. DOI: 10.1002/cam4.967
33 Pothoulakis C, Torre-Rojas M, Duran-Padilla MA, Gevorkian J, Zoras O, Chrysos E, Chalkiadakis G and Baritaki S: CRHR2/UCN2 signaling is a novel regulator of miR-7/YY1/FAS circuitry contributing to reversal of colorectal cancer cell resistance to FAS-mediated apoptosis. Int J Cancer 142(2): 334- 346, 2018. PMID: 28929494. DOI: 10.1002/ijc.31064
34 Zhu C, Sun Z, Li C, Guo R, Li L, Jin L, Wan R and Li S: Urocortin affects migration of hepatic cancer cell lines via differential regulation of cpla2 and ipla2. Cell Signal 26(5): 1125- 1134, 2014. PMID: 24518041. DOI: 10.1016/j.cellsig.2014.02.002
35 Pozzoli G, De Simone ML, Cantalupo E, Cenciarelli C, Lisi L, Boninsegna A, Dello Russo C, Sgambato A and Navarra P: The activation of type 1 corticotropin releasing factor receptor (CRF- R1) inhibits proliferation and promotes differentiation of neuroblastoma cells in vitro via p27 (KIP1) protein up-regulation and c-MYC mRNA down-regulation. Mol Cell Endocrinol 412: 205-215, 2015. PMID: 25960164. DOI: 10.1016/j.mce.2015.05.004
36 Larauche M, Kiank C and Tache Y: Corticotropin releasing factor signaling in colon and ileum: Regulation by stress and pathophysiological implications. J Physiol Pharmacol 60 Suppl 7:33-46, 2009. PMID: 20388944.
37 Ikeda K, Tojo K, Inada Y, Takada Y, Sakamoto M, Lam M, Claycomb WC and Tajima N: Regulation of urocortin I and its related peptide urocortin II by inflammatory and oxidative stresses in HL-1 cardiomyocytes. J Mol Endocrinol 42(6): 479-489, 2009. PMID: 19318426. DOI: 10.1677/jme-08-0151
38 Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL and Giordano FJ: Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 105(10): 3939-3944, 2008. PMID: 18308934. DOI: 10.1073/ pnas.0712366105
39 Carlson KW, Nawy SS, Wei ET, Sadée W, Filov VA, Rezsova VV, Slominski A and Quillan JM: Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res 21(2a): 1173-1179, 2001. PMID: 11396159.
論文の公開元へ
